-
Recently, the landmark INNOVATE clinical trial of CH Biomedical’s BrioVAD has been approved for Medicare coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Under this approval, the required medical device, along with its associated routine examinations and services will be reimbursed by Medicare.
-
On May 11, 2024, the Fuwai Hospital single-center long-term outcomes of CH Biomedical’s CH-VAD, a fully magnetically levitated ventricular assist device were published online in The Journal of Heart and Lung Transplantation (JHLT), a leading international journal in cardiothoracic surgery, under the title “Long-term outcomes of a novel fully magnetically levitated ventricular assist device for the treatment of advanced heart failure in China” [1].
-
From May 29 to June 1, 2024, the 70th Annual Meeting of the American Society for Artificial Internal Organs (ASAIO) was held in Baltimore, Maryland, USA. CH Biomedical was the only VAD company form China invited to participate, where it showcased its latest R&D achievements and breakthrough innovations, drawing significant attention from the international VAD community.
-
From April 10 to 13, 2024 (local time), the 44th Annual Conference of the International Society for Heart and Lung Transplantation (ISHLT 2024) was held at the Prague Congress Centre in the Czech Republic. At the ISHLT session titled “Spin Doctors and Heart Hotties: Unleashing the Future of MCS Devices,” Professor Wang Xianqiang from Fuwai Hospital made the first-ever international presentation of the long-term follow-up results for CH-VAD.
-
On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
-
CH Biomedical, recognized as a pioneering innovator in the global Ventricular Assist Device (VAD) field, earned a place on MIT Technology Review’s 2021 “50 Smartest Companies” list for its CH-VAD, a next-generation, fully magnetically levitated implantable left ventricular assist system (LVAD) — the first of its kind in China to be independently developed and approved by the National Medical Products Administration (NMPA).
